Generic Medicine Info
May be taken with or without food.
Congenital long QT syndrome or QT interval prolongation; bradycardia, recent acute MI, uncompensated heart failure, hypokalaemia, hypomagnesaemia. Concomitant admin or w/in 14 days of discontinuing MAOI treatment. Concomitant use w/ drug that prolong QT interval. Childn and adolescents <18 yr.
Special Precautions
May worsen depression, suicidal ideation and atypical behaviour in patients w/ psychiatric disorder. History of seizure and mania; hepatic impairment. CYP2C19 poor metabolisers. Avoid withdrawal reactions by gradual dose reduction. Pregnancy and lactation. Monitoring Parameters Closely monitor for possible depression worsening, suicidality or unusual changes in behaviour and serotonin syndrome or neuroleptic malignant syndrome (NMS)-like signs and symptoms. Periodically monitor serum electrolytes (e.g. K and Mg) before and during therapy. Monitor ECG in at-risk patients.
Adverse Reactions
Hyponatraemia (reversible); syndrome of inappropriate antidiuretic hormone secretion (SIADH); haemorrhage or bleeding; somnolence, insomnia, dizziness, asthenia, anxiety, fatigue, yawning; nausea, dry mouth, diarrhoea, dyspepsia, anorexia, vomiting, abdominal pain; sweating; decreased libido, ejaculation dysfunction, impotence in male patients, dysmenorrhoea; myalgia, arthralgia, fever; upper respiratory tract, rhinitis, sinusitis.
Potentially Fatal: Dose-dependent QT interval prolongation; torsade de pointes; ventricular tachycardia; sudden death. Increased risk of suicidal thinking and behaviour especially in childn and adolescents.
Drug Interactions
May increase anticoagulant effect w/ drugs affecting haemostatis (e.g. warfarin). Increased risk of hypomania w/ sibutramine. Increased lowering seizure threshold w/ TCAs and other SSRIs.
CIMS Class
ATC Classification
N06AB04 - citalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.
Disclaimer: This information is independently developed by CIMS based on citalopram from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in